Critical Care (Sep 2021)

Differences in mortality in critically ill elderly patients during the second COVID-19 surge in Europe

  • Christian Jung,
  • Jesper Fjølner,
  • Raphael Romano Bruno,
  • Bernhard Wernly,
  • Antonio Artigas,
  • Bernardo Bollen Pinto,
  • Joerg C. Schefold,
  • Georg Wolff,
  • Malte Kelm,
  • Michael Beil,
  • Sigal Sviri,
  • Peter Vernon van Heerden,
  • Wojciech Szczeklik,
  • Miroslaw Czuczwar,
  • Michael Joannidis,
  • Sandra Oeyen,
  • Tilemachos Zafeiridis,
  • Finn H. Andersen,
  • Rui Moreno,
  • Susannah Leaver,
  • Ariane Boumendil,
  • Dylan W. De Lange,
  • Bertrand Guidet,
  • Hans Flaatten,
  • , COVIP Study Group

DOI
https://doi.org/10.1186/s13054-021-03739-7
Journal volume & issue
Vol. 25, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background The primary aim of this study was to assess the outcome of elderly intensive care unit (ICU) patients treated during the spring and autumn COVID-19 surges in Europe. Methods This was a prospective European observational study (the COVIP study) in ICU patients aged 70 years and older admitted with COVID-19 disease from March to December 2020 to 159 ICUs in 14 European countries. An electronic database was used to register a number of parameters including: SOFA score, Clinical Frailty Scale, co-morbidities, usual ICU procedures and survival at 90 days. The study was registered at ClinicalTrials.gov (NCT04321265). Results In total, 2625 patients were included, 1327 from the first and 1298 from the second surge. Median age was 74 and 75 years in surge 1 and 2, respectively. SOFA score was higher in the first surge (median 6 versus 5, p < 0.0001). The PaO2/FiO2 ratio at admission was higher during surge 1, and more patients received invasive mechanical ventilation (78% versus 68%, p < 0.0001). During the first 15 days of treatment, survival was similar during the first and the second surge. Survival was lower in the second surge after day 15 and differed after 30 days (57% vs 50%) as well as after 90 days (51% vs 40%). Conclusion An unexpected, but significant, decrease in 30-day and 90-day survival was observed during the second surge in our cohort of elderly ICU patients. The reason for this is unclear. Our main concern is whether the widespread changes in practice and treatment of COVID-19 between the two surges have contributed to this increased mortality in elderly patients. Further studies are urgently warranted to provide more evidence for current practice in elderly patients. Trial registration number NCT04321265 , registered March 19th, 2020.

Keywords